Search

Your search keyword '"Bardier, Armelle"' showing total 26 results
Start Over Author "Bardier, Armelle"
26 results on '"Bardier, Armelle"'

2. Active surveillance for low-grade appendiceal mucinous neoplasm (LAMN)

Author

Mouawad Christian, Bardier Armelle, Wagner Mathilde, Doat Solène, Djelil Dahbia, Fawaz Jade, and Pocard Marc

Subjects
appendix, low-grade mucinous neoplasm, active surveillance, Medicine, Specialties of internal medicine, RC581-951
Abstract

Due to the scarcity of low-grade appendiceal mucinous neoplasm (LAMN), there is an absence of systematized guidelines concerning its management, especially after incidental finding on an appendiceal specimen. In this study, we evaluate the active surveillance (AS) strategy adopted for a series of patients diagnosed with LAMN on resection specimens who were considered to have a low risk of pseudomyxoma progression.

Published
2023
Full Text
View/download PDF

3. Réseau RENAPE : vers une meilleure équité d’accès aux soins et à l’expertise pour les patients atteints de cancers rares du péritoine

Author

Bardier, Armelle, Ben-Rejeb, Houda, Bertheau, Philippe, Benzerdjeb, Nazim, Bibeau, Frédéric, Bouhidel, Fatiha, Broudin, Choé, Charissoux, Aurélie, Chevallier, Anne, Dartigues, Peggy, Fontaine, Juliette, Heymann, Marie-Françoise, Illac-Vauquelin, Claire, Isaac, Sylvie, Kaci, Rachid, Kassem, Maysoun, Khellaf, Lakdhar, Lang-Averous, Gerlinde, Laverriere, Marie-Hélène, Lemaistre, Anne-Isabelle, Leroux-Broussier, Agnès, Mery-Lamarche, Eliane, Poizat, Flora, Svrcek, Magali, Valmary-Degano, Séverine, Verriele, Véronique, Villeneuve, Laurent, Odin, Cécile, Bonnefoy, Isabelle, Pichon, Patricia, and Valmary-Degano, Severine

Published
2024
Full Text
View/download PDF

5. Réseau RENAPE : vers une meilleure équité d’accès aux soins et à l’expertise pour les patients atteints de cancers rares du péritoine

Author

Villeneuve, Laurent, primary, Odin, Cécile, additional, Bonnefoy, Isabelle, additional, Pichon, Patricia, additional, Valmary-Degano, Severine, additional, Bibeau, Frédéric, additional, Bardier, Armelle, additional, Ben-Rejeb, Houda, additional, Bertheau, Philippe, additional, Benzerdjeb, Nazim, additional, Bouhidel, Fatiha, additional, Broudin, Choé, additional, Charissoux, Aurélie, additional, Chevallier, Anne, additional, Dartigues, Peggy, additional, Fontaine, Juliette, additional, Heymann, Marie-Françoise, additional, Illac-Vauquelin, Claire, additional, Isaac, Sylvie, additional, Kaci, Rachid, additional, Kassem, Maysoun, additional, Khellaf, Lakdhar, additional, Lang-Averous, Gerlinde, additional, Laverriere, Marie-Hélène, additional, Lemaistre, Anne-Isabelle, additional, Leroux-Broussier, Agnès, additional, Mery-Lamarche, Eliane, additional, Poizat, Flora, additional, Svrcek, Magali, additional, Valmary-Degano, Séverine, additional, and Verriele, Véronique, additional

Published
2024
Full Text
View/download PDF

6. Management of Pathogenic CDH1 Variant Carriers Within the FREGAT Network: A Multicentric Retrospective Study

Author

Bres, Capucine, Voron, Thibault, Benhaim, Leonor, Bergeat, Damien, Parc, Yann, Karoui, Mehdi, Genser, Laurent, Pe[Combining Acute Accent]re[Combining Acute Accent], Guillaume, Demma, Jonathan A., Bacoeur-Ouzillou, Ophe[Combining Acute Accent]lie, Lebreton, Gil, Thereaux, Jeremie, Gronnier, Caroline, Dartigues, Peggy, Svrcek, Magali, Bouzille[Combining Acute Accent], Guillaume, Bardier, Armelle, Brunac, Anne C., Roche, Brigitte, Darcha, Claude, Bazille, Celine, Doucet, Laurent, Belleannee, Genevieve, Lejeune, Sophie, Buisine, Marie P., Renaud, Florence, Nuytens, Frederiek, Benusiglio, Patrick R., Veziant, Julie, Eveno, Clarisse, and Piessen, Guillaume

Published
2022
Full Text
View/download PDF

10. Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study

Author

Perkins, Geraldine, Svrcek, Magali, Bouchet-Doumenq, Cecile, Voron, Thibault, Colussi, Orianne, Debove, Clotilde, Merabtene, Fatiha, Dumont, Sylvie, Sauvanet, Alain, Hammel, Pascal, Cros, Jerome, André, Thierry, Bachet, Jean-Baptiste, Bardier, Armelle, Douard, Richard, Meatchi, Tchao, Peschaud, Frederique, Emile, Jean-Francois, Cojean-Zelek, Isabelle, Laurent-Puig, Pierre, and Taieb, Julien

Published
2019
Full Text
View/download PDF

12. Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?

Author

Passot, Guillaume, Kim, Bradford J., Glehen, Olivier, Mehran, Reza J., Kopetz, Scott E., Goere, Diane, Overman, Michael J., Pocard, Marc, Marchal, Frédéric, Conrad, Claudius, Aloia, Thomas A., Vauthey, Jean-Nicolas, Chun, Yun Shin, Abba, Julio, Abboud, Karine, Alyami, Mohammad, Arvieux, Catherine, Asnacios, Amani, Averous, Gerlinde, Bakrin, Naoual, Bardier, Armelle, Rejeb, Houda Ben, Bereder, Jean-Marc, Bernard, Jean-Louis, Bibeau, Frédéric, Bonnefoy, Isabelle, Borg, Christophe, Boschetti, Gilles, Bouarioua, Nadia, Bouche, Olivier, Bouzard, Dominique, Brigand, Cécile, Cacheux, Wulfran, Capitain, Olivier, Carrère, Sébastien, Carretier, Michel, Castel, Benjamin, Chauvenet, Marion, Chevallier, Anne, Coffin, Benoît, Costan, Cristina, Cotte, Eddy, Courvoisier, Thomas, Dahan, Laetitia, Dartigues, Peggy, De Chaisemartin, Cécile, Dechelotte, Pierre, Deguelte-Lardière, Sophie, Delpero, Jean-Robert, Del Grande, Jean, Demarchi, Martin, Desandes, Emmanuel, Desolneux, Grégoire, Dufour, Patrick, Dumont, Frédéric, Durand-Fontanier, Sylvaine, Eveno, Clarisse, Evrard, Serge, Facy, Olivier, Farkhondeh, Fereshteh, Fontaine, Juliette, Gagniere, Johan, Galais, Marie-Pierre, Ghouti, Laurent, Gilly, François-Noël, Goasguen, Nicolas, Gornet, Jean-Marc, Gourdiole, Pierre, Guerin-Meyer, Véronique, Guilloit, Jean-Marc, Guimbaud, Rosine, Guyon, Frédéric, Heyd, Bruno, Heymann, Marie-Françoise, Isaac, Sylvie, Jouet, Pauline, Jourdan-Enfer, Peggy, Jouve, Jean-Louis, Kaci, Rachid, Karoui, Mehdi, Kianmanesh, Reza, Kirzin, Sylvain, Kurtz, Jean-Emmanuel, Labrousse, François, Lebrun-Ly, Valérie, Lefevre, Jérémie, Lelong, Bernard, Lemaistre, Anne-Elisabeth, Leroux-Broussier, Agnès, Levillain, Pierre, Linot, Benjamin, Dico, Réa Lo, Loi, Valéria, Lorimier, Gérard, Mahammat, Abakar, Malka, David, Marchal, Frédéric, Mariani, Antoine, Mariani, Pascale, Mariette, Christophe, Martin, Laurent, Meeus, Pierre, Meffert, Jean-Luc, Messager, Mathieu, Michel, Pierre, Msika, Simon, Muron, Thierry, Noel, Georges, Ortega-Deballon, Pablo, Paquette, Brice, Peoc’h, Michel, Petorin, Caroline, Peyrat, Patrice, Pezet, Denis, Piessen, Guillaume, Pirro, Nicolas, Pocard, Marc, Poizat, Flora, Porcheron, Jack, Poulet, Anaïs, Portales, Fabienne, la Denise, Justine Prost a, Quenet, François, Rat, Patrick, Rebischung, Christine, Regimbeau, Jean-Marc, Rivoirard, Romain, Rohr, Serge, Rougier, Philippe, Rousselot, Pierre, Saban-Roche, Léa, Sabate, Jean-Marc, Sabbagh, Charles, Sabourin, Jean-Christophe, Samalin-Scalzi, Emmanuelle, Seitz, Jean-François, Selves, Janick, Senellart, Helène, Serrano, Martine, Sgabura, Olivia, Sielezneff, Igor, Svrcek, Magali, Taibi, Abdelkader, Taieb, Julien, Thibaudeau, Emilie, Tougeron, David, Tuech, Jean-Jacques, Valmary-Degano, Séverine, Vaudoyer, Delphine, Verriele-Beurrier, Véronique, Villeneuve, Laurent, Volet, Julien, Wernert, Romuald, Ychou, Marc, You, Benoît, Zaanan, Aziz, Zinzindohoue, Franck, and on behalf of the BIG-RENAPE Working Group

Published
2017
Full Text
View/download PDF

14. hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status

Author

Raffenne, Jerome, Nicolle, Remy, Puleo, Francesco, Corre, Delphine Le, Boyez, Camille, Marechal, Raphael, Emile, Jean François, Demetter, Peter, Bardier, Armelle, Laurent-Puig, Pierre, Mestier, Louis de, Paradis, Valerie, Couvelard, Anne, VanLathem, Jean Luc, MacKey, John R., Bachet, Jean-Baptiste, Svrcek, Magali, and Cros, Jerome

Subjects
pancreatic adenocarcinoma, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, hENT1, Gemcitabine, Article
Abstract

Gemcitabine is still one of the standard chemotherapy regimens for pancreatic ductal adenocarcinoma (PDAC). Gemcitabine uptake into tumor cells is mainly through the human equilibrative nucleoside transport 1 (hENT1). It was therefore proposed as a potential predictive biomarker of gemcitabine efficacy but reports are conflicting, with an important heterogeneity in methods to assess hENT1 expression. A multicenter cohort of 471 patients with a resected PDAC was used to assess simultaneously the predictive value of the 2 best described hENT1 antibodies (10D7G2 and SP120). Three additional antibodies and the predictive value of hENT1 mRNA were also tested on 251 and 302 patients, respectively. hENT1 expression was assessed in 54 patients with matched primary tumors and metastases samples. The 10D7G2 clone was the only hENT1 antibody whose high expression was associated with a prolonged progression free survival and overall survival in patients who received adjuvant gemcitabine. hENT1 mRNA level was also predictive of gemcitabine benefit. hENT1 status was concordant in 83% of the cases with the best concordance in synchronous metastases. The 10D7G2 clone has the best predictive value of gemcitabine benefit in PDAC patients. Since it is not commercially available, hENT1 mRNA level could represent an alternative to assess hENT1 status.

Published
2019

16. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status

Author

Cohen, Romain, primary, Hain, Elisabeth, additional, Buhard, Olivier, additional, Guilloux, Agathe, additional, Bardier, Armelle, additional, Kaci, Rachid, additional, Bertheau, Philippe, additional, Renaud, Florence, additional, Bibeau, Frédéric, additional, Fléjou, Jean-François, additional, André, Thierry, additional, Svrcek, Magali, additional, and Duval, Alex, additional

Published
2019
Full Text
View/download PDF

18. Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers.

Author

Karoui, Mehdi, Rullier, Anne, Luciani, Iain, Bonnetain, Franck, Auriault, Marie-Luce, Sarran, Antony, Monges, Geneviève, Trillaud, Hervé, Le Malicot, Karine, Leroy, Karen, Sobhani, Iradj, Bardier, Armelle, Moreau, Marie, Brindel, Isabelle, Seitz, Jean François, and Taie, Julien

Abstract

Background: Perioperative chemotherapy has proven valuable in several tumors, but not in colon cancer (CC). Objective: The aim of this study was to evaluate the efficacy and safety of perioperative chemotherapy in patients with locally advanced nonmetastatic CC. Methods: This is a Frenchmulticenter randomized phase II trial in patientswith resectable high-risk T3, T4, and/or N2 CC on baseline computed tomography (CT) scan. Patients were randomized to receive either 6 months of adjuvant FOLFOXafter colectomy(control) or perioperativeFOLFOXfor 4 cycles before surgery and 8 cycles after (FOLFOXperi-op). InRAS wild-type patients, a third arm testing perioperative FOLFOX-cetuximab was added. Tumor Regression Grade (TRG1) of Ryan et al was the primary endpoint. Secondary endpoints were toxicity, perioperative morbidity, and quality of surgery. Results: A total of 120 patients were enrolled. At interim analysis, the FOLFOX-cetuximab arm was stopped (lack of efficacy). The remaining 104 patients (control, n ¼ 52; FOLFOX preop n ¼ 52) represented our intention-totreat population. In the FOLFOX perioperative group, 96% received the scheduled 4 cycles before surgery. R0 resection and complete mesocolic excision rate were 94%and 93%, respectively. Overall mortality and morbidity rateswere similar in both groups. Perioperative FOLFOXchemotherapy did not improve major pathological response rate (TRG1¼8%) butwas associated with a significant pathological regression (TRG1-2 ¼ 44% vs 8%, P < 0.001) and a trend to tumor downstaging as compared to the control group. CT scan criteria were associated with a 33% rate of overstaging in control group. Conclusions: Perioperative FOLFOX for locally advanced resectable CC is feasible with an acceptable tolerability but is not associated with an increased major pathological response rate as expected. However, perioperative FOLFOX induces pathological regression and downstaging. Better preoperative staging tools are needed to decrease the risk of overtreating patients [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

20. Clinical and molecular characterization of patients with metastatic colorectal cancer harbouring DNA mismatch repair deficiency.

Author

Cohen, Romain, primary, Hain, Elisabeth, additional, Cervera, Pascale, additional, Buhard, Olivier, additional, Dumont, Sylvie, additional, Bardier, Armelle, additional, Bachet, Jean-Baptiste, additional, Gornet, Jean Marc, additional, Dumont, Sarah, additional, Kaci, Rachid, additional, Bertheau, Philippe, additional, Renaud, Florence, additional, Bibeau, Frederic, additional, Parc, Yann, additional, Duval, Alex, additional, Svrcek, Magali, additional, and Andre, Thierry, additional

Published
2017
Full Text
View/download PDF

21. Genomic profiling of ampullary adenocarcinoma (AA): Insights from a comparative analysis of pancreatic and intestinal adenocarcinoma and opportunities for targeted therapies use.

Author

Perkins, Geraldine, primary, Bouchet-Doumenq, Cecile, additional, Svrcek, Magali, additional, Colussi, Orianne, additional, Voron, Thibault, additional, Sauvanet, Alain, additional, Hammel, Pascal, additional, Cros, Jerome, additional, Paye, Francois, additional, Andre, Thierry, additional, Vaillant, Jean-Christophe, additional, Bachet, Jean Baptiste, additional, Bardier, Armelle, additional, Berger, Anne, additional, Meatchi, Tchao, additional, Nordlinger, Bernard, additional, Emile, Jean-Francois, additional, Cojean-Zelek, Isabelle, additional, Taieb, Julien, additional, and Laurent-Puig, Pierre, additional

Published
2017
Full Text
View/download PDF

22. Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial – the PRODIGE 22 - ECKINOXE trial

Author

Karoui, Mehdi, primary, Rullier, Anne, additional, Luciani, Alain, additional, Bonnetain, Franck, additional, Auriault, Marie-Luce, additional, Sarran, Antony, additional, Monges, Geneviève, additional, Trillaud, Hervé, additional, Le Malicot, Karine, additional, Leroy, Karen, additional, Sobhani, Iradj, additional, Bardier, Armelle, additional, Moreau, Marie, additional, Brindel, Isabelle, additional, Seitz, Jean François, additional, and Taieb, Julien, additional

Published
2015
Full Text
View/download PDF

26. Generalized Caseview applied to prostate cancer prognosis.

Author

Levy PP, Bardier A, Doublet JD, and Sibony M

Subjects
Humans, Male, Pattern Recognition, Automated methods, Reproducibility of Results, Sensitivity and Specificity, Artificial Intelligence, Biopsy methods, Computer Graphics, Decision Support Systems, Clinical, Diagnosis, Computer-Assisted methods, Prostatic Neoplasms pathology, User-Computer Interface
Abstract

The interpretation of results of any study using large tables with series of numbers is always difficult. Generalized Case View Method (GCm) allows translating these tables of numbers into an image. The Method identifies each informational entity in the table with a 'pixel', forming what we call an 'infoxel'. The sum of all informational entities becomes an image, the Generalized Caseview. The method consists of two steps: the first one is to define the reference frame while the second is to visualize data through the reference frame. The 'infoxels' that constitute the reference frame should be organized according to three criteria: binary, nominal and ordinal. Here this method has been applied to visualize the results of a study about prostate cancer spread. This paper exemplifies the usefulness of associating a classical statistical tool with Generalized Caseview method to solve a biomedical problem.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results